FDA Clears Paradromics’ Connexus Brain Chip - First Human Trial

Paradromics, a brain-computer interface (BCI) company based in Austin, Texas, has received FDA approval to begin a human study of its Connexus BCI — a fully implantable brain chip designed for long-term use. The Investigational Device Exemption (IDE) granted for its Connect-One Early Feasibility Study marks a milestone: it’s the first time the FDA has authorized a high-data-rate implantable BCI specifically for restoring speech. 

Connexus is constructed from medical-grade materials — a titanium-alloy body with more than 400 ultra-fine platinum-iridium electrodes, each thinner than a human hair. These electrodes will be placed just beneath the brain’s surface in the motor cortex, the area that controls articulation. On-chip processing captures brain signals, which are then wirelessly transmitted out of the body through an internal transceiver and a wearable external one. The external unit charges inductively (like a wireless phone) and streams data to a computer running AI-powered language models. That system decodes neural patterns into text or synthesized speech, letting users communicate. 

The trial will begin with only two participants, each receiving a Connexus implant about 7.5 mm wide inserted 1.5 mm into the motor cortex. These volunteers will listen to sentences, then imagine speaking them in their mind. The device learns their neural “speech” patterns by mapping brain activity to sound, enabling real-time synthetic voice generation. 

Paradromics will also assess whether Connexus can pick up neural patterns linked to imagined hand movements—potentially allowing cursor control. If the first phase goes well, the company hopes to expand to 10 participants later, including some who might receive two implants to boost signal resolution. 

Paradromics CEO Matt Angle described the approval as “very exciting.” From an academic standpoint, BCI researcher Mariska Vansteensel noted that fully implantable systems like this are the future for clinical applications. 

Key Takeaways:

The FDA has approved a human trial for Paradromics’ fully implantable Connexus brain chip, a BCI designed to help people with paralysis restore speech.

Connexus uses over 400 microelectrodes, wirelessly transmits brain signals, and converts neural activity into text or synthesized voice with AI.

The initial study involves two participants, with future plans to expand; it may also enable cursor control via

imagined hand movements.

Adapted From 

https://newatlas.com/medical-devices/human-trial-experimental-brain-chip-connexus/

Nature Link

https://www.nature.com/articles/d41586-025-03849-0